{
    "title": "Green light for AstraZeneca's immunotherapy bladder cancer drug revolution",
    "url": "https://www.dailymail.co.uk/money/markets/article-4466928/Green-light-bladder-cancer-drug-revolution.html",
    "date": "2017-05-02",
    "keywords": [
        "cancer",
        "drug",
        "treatment",
        "imfinzi",
        "immunotherapy",
        "astrazeneca",
        "immune",
        "approval",
        "market",
        "bladder",
        "company",
        "system",
        "soriot",
        "blockbuster",
        "firm",
        "decline",
        "crestor",
        "milestone",
        "development",
        "immunooncology",
        "bodys",
        "share",
        "boss",
        "protein",
        "chemotherapy",
        "pfizer",
        "kind",
        "pay",
        "ability",
        "lung",
        "combination",
        "light",
        "win",
        "bestselling",
        "cholesterol",
        "medicine",
        "genericsthe",
        "competitionimfinzi",
        "food",
        "administration",
        "research",
        "fight",
        "competitionthe",
        "class",
        "thing",
        "number",
        "sector",
        "order",
        "flock",
        "housebuilder",
        "bovis",
        "merger",
        "aberdeen",
        "star",
        "brother",
        "law",
        "fraud",
        "profit",
        "article",
        "week",
        "glaxosmithkline",
        "emma",
        "walmsley",
        "year",
        "revolution",
        "work",
        "body",
        "pdl1the",
        "disease",
        "hoped",
        "side",
        "effectsthe",
        "roche",
        "merk",
        "co",
        "cost",
        "month",
        "america",
        "eu",
        "drugthe",
        "boost",
        "shareholder",
        "revolt",
        "package",
        "meeting",
        "london",
        "loss",
        "patent",
        "crestorbut",
        "takeover",
        "breakthrough",
        "gsk",
        "opportunity",
        "therapythe",
        "trial",
        "june",
        "july",
        "benefit",
        "tremelimumab",
        "compoundif"
    ],
    "category": [
        "money",
        "markets"
    ]
}